Are Investors Wrong About Raptor Pharmaceuticals?

Short-sellers have pushed into Raptor Pharmaceuticals in a big way lately. Here's why.

Jun 26, 2014 at 5:00PM

A rapidly increasing short interest in a stock is sometimes a good signal that an investment may not be a good idea. Even so, it's critical to understand why shorts are moving into the stock before making any investment decisions.

Raptor Pharmaceuticals (NASDAQ:RPTP) saw its shares rise by more than 300% following the 2013 FDA approval of Procysbi (RP103), the company's orphan drug for nephropathic cystinosis. Although the stock gave back some of that monstrous gain earlier this year, Raptor shares have started to move higher again over the past month.

Short-sellers have nonetheless moved into the stock in lockstep with Raptor's rising share price. With that in mind, let's consider two reasons why shorts think this stock is setting up for a reversal.  

RPTP Chart

RPTP data by YCharts.

Reason No. 1
While getting a drug approved is no small feat, it's only half the battle. Successfully commercializing a drug requires substantial resources and know-how. This is always a major challenge for biopharmas like Raptor that are transitioning from a developmental to a commercial operation. 

Following Procysbi's approval, Raptor's selling, general, and administrative expenses increased markedly. Raptor reported last month that such costs hit $12.1 million in the first quarter, a 53% increase over the same period a year ago. Interest expense also climbed to $2.8 million for the quarter, compared to only $0.7 million for the same period a year ago

Because of these costs associated with commercializing Procysbi and rising research expenses, Raptor lost $14.9 million in the first quarter (excluding one-time costs), or $0.24 per share, despite earning $12.1 million  in net product sales.

Reason No. 2
Raptor also provided a much lower annual guidance for Procysbi sales than expected by Wall Street. Specifically, the company expects annual sales to come in between $55 to $65 million for 2014. The Street was expecting a figure closer to $70 million. 

Although Raptor didn't provide much insight into this annual sales projection, Procysbi's commercial opportunity in Europe may be smaller than previously believed. Experts believe there are fewer patients in Europe afflicted with nephropathic cystinosis than indicated by earlier sales models. This could be a strong contributor to Raptor's weak annual sales guidance for Procysbi. 

More important, consider what this lower guidance means in terms of Raptor's valuation. At its present market cap of roughly $700 million, Raptor's shares are trading at about 11 times annual revenue.

While this may not be an astronomical figure for a biopharma, it's also not cheap. And considering that overall expenses are expected to increase for the foreseeable future, Raptor's bottom line may not improve enough to create a compelling valuation going forward.

Foolish wrap-up
While Raptor's problems appear to center around its sudden stock-price rise and disappointing sales projections, there are reasons to be optimistic. Specifically, Raptor is developing RP103 as a potential treatment for nonalcoholic fatty liver disease, or NAFLD, and Huntington's disease. Raptor's midstage trial for NAFLD in children is now fully enrolled, with top-line results expected in early 2015.

NAFLD and related liver diseases are believed to be potentially lucrative indications. Earlier this year, shares of Intercept Pharmaceuticals (NASDAQ:ICPT) more than tripled after the company reported positive top-line results for obeticholic acid, its experimental treatment for nonalcoholic steatohepatitis.

Moreover, top biotechs such as Gilead Sciences (NASDAQ:GILD) have taken a keen interest in developing drugs for liver diseases in hopes of capturing some of this rapidly growing market. Gilead's simtuzumab is in a midstage trial for the treatment of liver fibrosis. 

Raptor's midstage trial for NAFLD in children could thus be a major catalyst for the stock in the next 12 months and may create interest in a possible takeover. 

I believe Raptor's rising short interest is linked to the difficulties associated with commercializing a new drug and an uncertain market opportunity for a rare disease. At the same time, Raptor has other irons in the fire that are worth watching closely. 

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

 

George Budwell has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers